Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reltecimod in Sepsis-Associated Acute Kidney Injury
NCT03403751Phase 3Terminated
- Sponsor
- Atox Bio
- Start
- May 2018
- Primary completion
- Dec 2019
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in sepsis-associated acute kidney injury (S-AKI) comparing Reltecimod with Placebo (2 arms). Primary endpoints: Freedom From Durable Loss of Renal Function at Day 28, Serious Adverse Events at 28 days and 1 more. Started May 2018; status: terminated.
02
Drugs
reltecimod
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on NCT03403751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403751.